

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

(Stock Code: 3320)

**RESIGNATION OF EXECUTIVE DIRECTOR,  
VICE PRESIDENT AND BOARD COMMITTEES' MEMBER  
AND AUTHORIZED REPRESENTATIVE  
AND  
APPOINTMENT OF CHIEF FINANCIAL OFFICER  
AND  
CHANGE OF COMPANY SECRETARY AND AUTHORIZED  
REPRESENTATIVE**

The Board announces that, with effect from 13 June 2023:

- (1) Mdm. Weng Jingwen has resigned as an executive director, the chief financial officer, vice president, a member of the executive committee and corporate governance committee, and an authorized representative of the Company due to her personal career development;
- (2) Mdm. Deng Rong has been appointed as the Chief Financial Officer of the Company;
- (3) Mr. Lo Chi Lik Peter has resigned from the company secretary of the Company; and
- (4) Mr. So Yiu Fung has been appointed as the company secretary and an authorised representative of the Company.

**RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER, VICE PRESIDENT, BOARD COMMITTEES' MEMBER AND AUTHORIZED REPRESENTATIVE**

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) announces, with effect from 13 June 2023, Mdm. Weng Jingwen (“**Mdm. Weng**”) has resigned as an executive director, the chief financial officer, vice president, a member of the executive committee of the Company (the “**Executive Committee**”) and the corporate governance committee of the Company (the “**Corporate Governance Committee**”), and an authorized representative of the Company due to her personal career development.

Upon Mdm. Weng's resignation as a member of the Executive Committee, the number of members of the Executive Committee will fall below the minimum requirements as stipulated by the terms of reference of the Executive Committee. The Company is currently actively identifying suitable candidate to fill the vacancy as soon as practicable.

Mdm. Weng has confirmed that she has no disagreement with the Board and there are no other matters in relation to his resignation that need to be brought to the attention of the holders of securities of the Company. The Board would like to take this opportunity to express its gratitude and appreciation to Mdm. Weng for her contributions to the Company.

## **APPOINTMENT OF CHIEF FINANCIAL OFFICER**

The Board announces that Mdm. Deng Rong (“**Mdm. Deng**”) has been appointed as the Chief Financial Officer of the Company with effect from 13 June 2023. The biographical details of Mdm. Deng are as follows:

**Mdm. Deng Rong**, aged 44, has previously held various positions within China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司), including the Head of Financial Accounting and Tax Management Department at the Financial Management Center, General Manager of the Accounting Management Department at the Financial Management Center, General Manager of the Financial Management Center, General Manager of the Financial Shared Services Center, Director of Accounting Management, General Manager of the Business Financial Management Department, and General Manager of the Financial Functional Management Department. She has also served as Vice President, Board Secretary, and Chief Financial Officer at Dong-E-E-Jiao Co., Ltd (東阿阿膠股份有限公司). Mdm. Deng holds a Bachelor's degree in Accounting from Central South University (中南大學) and a Master's degree in Management from Beijing Jiaotong University (北京交通大學). She is a certified board secretary recognized by the Shenzhen Stock Exchange.

The Board takes this opportunity to extend a warm welcome to Mdm. Deng for her new appointment.

## **CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE**

The Board further announces that, with effect from 13 June 2023, Mr. Lo Chi Lik Peter (“**Mr. Lo**”) has resigned from the company secretary of the Company as he has reached his retirement age. Mr. Lo has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the holders of securities of the Company.

The Board is pleased to announce that, with effect from 13 June 2023, Mr. So Yiu Fung (“**Mr. So**”) has been appointed as the company secretary and an authorised representative of the Company. Mr. So, aged 41, currently serves as the group deputy company secretary of CR Corporate Affairs Limited. He has been appointed as the company secretary of China Resources Medical Holdings Company Limited (stock code: 1515) since July 2018, China Resources Cement Holdings Limited (stock code: 1313) since May 2022, China Resources Land Limited (stock code: 1109) since January 2023, China Resources Mixc Lifestyle Services Limited (stock code: 1209) since January 2023 and China Resources Power Holdings Company Limited (stock code: 836) since April 2023, respectively. Prior to that, Mr. So had served as the company secretary and an authorised representative of TUS International Limited (currently known as Titan Invo Technology Limited, stock code: 872), the deputy director of capital group of finance department of China Resources Land Limited (stock code: 1109), the senior company secretarial officer of the legal department of China Resources (Holdings) Company Limited, and had also worked for corporate finance advisory firms. He holds a Bachelor’s degree in civil engineering from The University of Hong Kong, and is a member of the Hong Kong Institute of Certified Public Accountants. Mr. So has over 15 years of experience in corporate finance, merger and acquisition, company secretary and accounting.

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Lo for his contributions to the Company and warmly welcomes Mr. So for his new appointment.

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Beijing, 13 June 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*